Dianthus Therapeutics, Inc. /DE/ Income Statement

Income Statement Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & Cost
Revenue -0.16M6.42M2.83M6.24M
Interest income
Interest Income - Total 4.76M17.36M
Interest expenses
Interest Expenses 0.16M
Interest Income - Net 4.76M17.36M
Operating Items
Research & Development 5.78M27.90M41.34M59.21M29.38M32.84M83.11M
Selling, General & Administrative 3.49M7.83M18.62M23.76M6.74M18.16M24.99M
Operating Expenses 9.27M35.73M59.96M82.97M36.12M51.00M108.10M
Operating Income -9.27M-35.73M-59.96M-82.97M-29.70M-48.17M-101.86M
EBIT -9.27M-35.73M-59.96M-82.97M-29.70M-48.17M-101.86M
Non-operating items
Interest & Investment Income 0.24M2.45M6.20M1.15M4.76M17.36M
Other Non Operating Income 0.14M-0.09M-0.55M
Non Operating Income -0.16M0.24M2.45M1.23M4.62M16.89M
Net income details
EBT -9.43M-35.49M-57.52M-76.77M-28.56M-43.41M-84.50M
Profit After Tax -9.43M-35.49M-57.52M-76.77M-28.50M-43.60M-85.00M
Income from Continuing Operations -9.43M-35.49M-57.52M-76.77M-28.56M-43.41M-84.50M
Consolidated Net Income -9.43M-35.49M-57.52M-76.77M-28.56M-43.41M-84.50M
Income towards Parent Company -9.43M-35.49M-57.52M-76.77M-28.56M-43.41M-84.50M
Preferred Dividend Payments 0.20M0.44M0.09M
Net Income towards Common Stockholders -9.73M-35.51M-57.60M-76.77M-28.56M-43.41M-84.50M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 2.15M2.07M2.44M3.02M3.67M3.78M14.82M29.60M
Shares Outstanding (Diluted Average) 0.87M5.15M33.31M
EBITDA -9.43M-35.49M-57.52M-76.75M-28.64M-43.35M-84.91M